Kelvin Neu
Directeur/Bestuurslid bij ZYMEWORKS INC.
Vermogen: - $ op 30-04-2024
Profiel
Kelvin M.
Neu is currently a Director at Zymeworks BC, Inc. and an Independent Director at Zymeworks, Inc. He previously served as an Independent Director at Idera Pharmaceuticals, Inc., Director at XOMA Corp., Director at diaDexus, Inc., Director at Aquinox Pharmaceuticals, Inc., Director at Prelude Therapeutics, Inc., Director at IGM Biosciences, Inc., and Partner at Baker Bros.
Advisors LP.
He also served as a Director at AnorMED, Inc. and Presidio Pharmaceuticals, Inc. Dr. Neu received his undergraduate degree from Princeton University and his doctorate from Harvard Medical School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ZYMEWORKS INC.
-.--% | 11-10-2023 | 0 ( -.--% ) | - $ | 30-04-2024 |
IGM BIOSCIENCES, INC.
-.--% | 28-02-2024 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Kelvin Neu
| Bedrijven | Functie | Begin |
|---|---|---|
| ZYMEWORKS INC. | Directeur/Bestuurslid | 01-03-2020 |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Directeur/Bestuurslid | 16-03-2020 |
Eerdere bekende functies van Kelvin Neu
| Bedrijven | Functie | Einde |
|---|---|---|
| IGM BIOSCIENCES, INC. | Directeur/Bestuurslid | 26-01-2021 |
| PRELUDE THERAPEUTICS INCORPORATED | Directeur/Bestuurslid | 25-01-2021 |
Baker Bros. Advisors LP
 Baker Bros. Advisors LP Investment ManagersFinance Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account. | Portefeuillebeheerder-Aandelen | 01-01-2021 |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Directeur/Bestuurslid | 09-08-2019 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Directeur/Bestuurslid | 04-06-2019 |
Opleiding van Kelvin Neu
| Princeton University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| XOMA CORPORATION | Health Technology |
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
| IGM BIOSCIENCES, INC. | Health Technology |
| ZYMEWORKS INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
Baker Bros. Advisors LP
Baker Bros. Advisors LP Investment ManagersFinance Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account. | Finance |
diaDexus, Inc. /Old/
 diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Presidio Pharmaceuticals, Inc.
 Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA. | Health Technology |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
AnorMED, Inc.
 AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | Health Technology |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |